Review: Malignant tracheo-esophageal fistula: Use of esophageal endoprosthesis

Spivak, Hadar; Katariya, Kushagra; Lo, Andy Y.; Harvey, James C.

doi:10.1002/(sici)1096-9098(199609)63:1<65::aid-jso13>3.0.co;2-o

Cited by 17 publications

(10 citation statements)

References 28 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data fit very well to the current literature. 22 The significantly increased 90-day mortality in AF patients as well as the overall survival data furthermore suggests that the majority of deaths in the AF group occur in the early postoperative course, implying that this severe postoperative complication directly affects perioperative mortality and subsequently survival.…”

Section: Discussionmentioning

confidence: 99%

Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy

Lindner

Lübbe

Müller

et al. 2016

Diseases of the Esophagus

View full text Add to dashboard Cite

Fistulas between the upper intestinal tract and the airway following esophagectomy are a rare and severe complication with significant mortality. Treatment and therapy are difficult and require a multidisciplinary approach. The objective of this retrospective study was to identify risk factors for these fistulas following esophagetcomy, and to assess their impact on the further clinical course and outcome. 211 patients undergoing Ivor-Lewis esophagectomy for esophageal cancer between 2005 and 2012 were included. The preoperative risk factors including the risk score according to Schröder et al. and the O-Physiological and Operative Severity Score (POSSUM) score, operative and postoperative parameters and the outcome were evaluated. 65% of all patients developed postoperative complications, including 12 patients that developed fistulas between the upper intestinal tract and the airway (airway fistulas [AF]; 5.6%). Neither patient related risk factors nor esophagus-specific risk scores correlated with occurrence of AF. Furthermore, surgical treatment and neoadjuvant treatment did not show any effect on development of AF in our patients. However, we could demonstrate that AF significantly impacted on length of hospital stay (AF 52 days vs. No-AF group 16 days, P < 0.001), incidence of major pulmonary complications (83.3% vs. 17.1%, P < 0.001), 90-day mortality (42% vs. 7.5%, P = 0.002) and overall survival (133 days vs. 636 days, P=0.029). With the current study, we could not identify any patient related risk factors, esophagus-specific risk scores or treatment related details that might be useful as predictors of AF after Ivor-Lewis esophagectomy. However, we confirmed that AF significantly impacted on outcomes. This highlights the urgent need for further studies on this rare but devastating complication after esophagectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy

Lindner

Lübbe

Müller

et al. 2016

Diseases of the Esophagus

View full text Add to dashboard Cite

show abstract

“…Tracheoesophageal fistula is associated with a poor prognosis 1–3 . The all‐cause 90‐day mortality rate associated with TEF approaches 80%; however, TEF secondary to lymphoma seems to be associated with a better prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…Tracheoesophageal fistula is associated with a poor prognosis. [1][2][3] The all-cause 90-day mortality rate associated with TEF approaches 80%; however, TEF secondary to lymphoma seems to be associated with a better prognosis. Perry et al demonstrated a 5-year survival rate of 62%−77% in patients with TEF related to lymphoma treated with either radiation or chemotherapy, suggesting that, in lymphoma patients, the survival rate is relatively unaffected by the presence of a TEF.…”

Section: Discussionmentioning

confidence: 99%

“…In this setting, it is generally not the intent to ever remove the stent. TEF rarely complicates the course of mediastinal lymphoma 1 . As lymphomas tend to be very sensitive to chemotherapy, TEFs frequently seal spontaneously with this therapy 2 .…”

Section: Introductionmentioning

confidence: 99%

“…TEF rarely complicates the course of mediastinal lymphoma. 1 As lymphomas tend to be very sensitive to chemotherapy, TEFs frequently seal spontaneously with this therapy. 2 Herein, we describe a young woman found to have Hodgkin's disease complicated by TEF that required emergent placement of an SEMS.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lymphoma and tracheoesophageal fistula: Indication for a removable esophageal stent

Bernal

Rochling

DiBaise

2005

Diseases of the Esophagus

View full text Add to dashboard Cite

Mediastinal lymphoma is a rare cause of tracheoesophageal fistula (TEF). While most reports described in the literature have been related to prior or concurrent chemoradiation therapy, TEF has rarely been reported as the initial presentation of lymphoma. We report on a young woman found to have Hodgkin's disease complicated by TEF that required emergent placement of an esophageal stent. The lymphoma was successfully treated and, due to stent-related symptoms, removal was desired but not technically possible. We discuss options that may prevent this predicament in the future.

show abstract

Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae

Muto

Ohtsu

Miyamoto

et al. 1999

Cancer

View full text Add to dashboard Cite

Review: Malignant tracheo-esophageal fistula: Use of esophageal endoprosthesis

Cited by 17 publications

References 28 publications

Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy

Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy

Lymphoma and tracheoesophageal fistula: Indication for a removable esophageal stent

Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae

Contact Info

Product

Resources

About